Measurement of Patient Reported Gastrointestinal (GI) and Health-Related Quality of Life (HRQL) Outcomes in Simultaneous Pancreas-Kidney Transplant Recipients.

Trial Profile

Measurement of Patient Reported Gastrointestinal (GI) and Health-Related Quality of Life (HRQL) Outcomes in Simultaneous Pancreas-Kidney Transplant Recipients.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Dec 2010

At a glance

  • Drugs Mycophenolate sodium (Primary)
  • Indications Pancreas transplant rejection; Renal transplant rejection
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 23 Dec 2010 Actual initiation date changed from Dec 2008 to Jan 2008 as reported by ClinicalTrials.gov.
    • 23 Dec 2010 Last checked against ClinicalTrials.gov record.
    • 18 Dec 2008 Planned number of patients changed from 130 to 32 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top